Pharmaceutical
Cannabis M&A, lounging in the future and an LSE downturn
Ripe for the Picking | Cannabis M&A predictions for 2022 Low stock prices are likely to motivate more cannabis mergers and acquisitions in 2022, reports Insider.
schumer
10stories
13 Declast updated
More in schumer
- CBD Market
Should CBD regulations come before cannabis reform?
Since broader federal cannabis reform could take quite some time, the Natural Products Association (NPA) penned an op-ed for Marijuana Moment reminding regulators that CBD, while legal, is still woefully under-regulated — and that it should be prioritized first.
- Cultivation
Will Tilray snap up an MSO pre-legalization?
Tilray CEO Irwin Simon says the company is actively shopping for the right multi-state cannabis operator to forge a path into the US market.
- Adult-Use
Phew! Booker clarifies his SAFE stance
Senator Cory Booker told Yahoo! Finance’s Zack Guzmán that — seemingly contrary to what he said last week — that he does in fact support the SAFE Banking Act after all.
- Adult-Use
Will midterms mess up US legalization?
Canadian LPs are banking on federal legalization in the US, but some are worried that it won’t happen before the 2022 midterm elections, when Democrats could lose control of Congress to Republicans, according to a Canadian Press report.
- Adult-Use
Curaleaf on the fast track to growth
Wakefield, Massachusetts-based Curaleaf reported record earnings for Q1 this week at US$260 million, up 170% year over year.
- Uncategorized
What’s better than a Super Bowl?
Good morning. Today is another post-Tom Brady Super Bowl Monday… Last week was a busy week one in cannabis last week – with a major acquisition and more (and more) US states looking toward legalization.
